VJHemOnc Podcast
Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!
Feb 21, 2025
In this insightful discussion, Vaishali Sanchorawala, a leading expert in amyloidosis from Boston University, and Ashutosh Wechalekar, a prominent hematologist from University College London, delve into the cutting-edge findings presented at the recent ASH meeting. They highlight breakthrough results from the ANDROMEDA trial, emphasizing the effectiveness of daratumumab VCD for AL amyloidosis treatment. The duo also explores advancements in risk stratification and the promising role of measurable residual disease and CAR T-cell therapy in enhancing patient care.
13:15
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The ANDROMEDA trial has established daratumumab combined with VCD as a superior new standard of care for AL amyloidosis, showing improved patient response and survival rates.
- Updated risk stratification methods for light-chain amyloidosis now integrate echocardiographic parameters, enhancing the identification of high-risk patients for tailored treatment strategies.
Deep dives
Advancements in AL Amyloidosis Treatment
The Andromeda trial has marked a significant breakthrough in the treatment of AL amyloidosis with the introduction of daratumumab combined with VCD (DARA-VCD) as a new standard of care. This trial demonstrated that 59% of patients treated with DARA-VCD achieved complete hematologic response compared to only 19% of those receiving VCD alone, indicating a much higher efficacy. Furthermore, the findings indicated improved overall survival and reduced organ deterioration, underscoring the treatment's effectiveness over traditional methods. The results from five years of follow-up suggest that this approach is set to replace autologous stem cell transplant, proving to be a well-tolerated option that enhances patient outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
